Home LiteratureArticle Details
PMID: 17075009 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells.

Circulation ·Vol. 114 ·No. 20 ·2006-11-14 ·Pages 2163-9

Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Zak V, Asahara T, Losordo DW

Abstract

We compared the therapeutic potential of purified mobilized human CD34+ cells with that of mobilized total mononuclear cells (tMNCs) for the preservation/recovery of myocardial tissue integrity and function after myocardial infarction (MI). CD34+ cells were purified from peripheral blood tMNCs of healthy volunteers by magnetic cell sorting after a 5-day administration of granulocyte colony-stimulating factor. Phosphate-buffered saline (PBS), 5x10(5) CD34+ cells/kg, 5x10(5) tMNCs/kg (low-dose MNCs [loMNCs]), or a higher dose of tMNCs (hiMNCs) containing 5x10(5) CD34+ cells/kg was transplanted intramyocardially 10 minutes after the induction of MI in athymic nude rats. Hematoxylin and eosin staining revealed that moderate to severe hemorrhagic MI on day 3 was more frequent in the hiMNC group than in the PBS and CD34+ cell groups. Immunostaining for human-specific CD45 revealed abundant distribution of hematopoietic/inflammatory cells derived from transplanted cells in the ischemic myocardium of the hiMNC group. Capillary density on day 28 was significantly greater in the CD34+ cell group (721.1+/-19.9 per 1 mm2) than in the PBS, loMNC, and hiMNC groups (384.7+/-11.0, 372.5+/-14.1, and 497.5+/-24.0 per 1 mm2) (P<0.01). Percent fibrosis area on day 28 was less in the CD34(+) cell group (15.6+/-0.9%) than in the PBS, loMNC, and hiMNC groups (26.3+/-1.2%, 27.5+/-1.8%, and 22.2+/-1.8%) (P<0.05). Echocardiographic fractional shortening on day 28 was significantly higher in the CD34+ cell group (30.3+/-0.9%) than in the PBS, loMNC, and hiMNC groups (22.7+/-1.5%, 23.4+/-1.1%, and 24.9+/-1.7%; P<0.05). Echocardiographic regional wall motion score was better preserved in the CD34+ cell group (21.8+/-0.5) than in the PBS, loMNC, and hiMNC groups (25.4+/-0.4, 24.9+/-0.4, and 24.1+/-0.6; P<0.05). CD34+ cells exhibit superior efficacy for preserving myocardial integrity and function after MI than unselected circulating MNCs.

MeSH Terms
Animals Antigens, CD34/metabolism Cell Differentiation Echocardiography Female Hemorrhage/etiology Humans Monocytes/metabolism,pathology,transplantation Myocardial Infarction/complications,pathology,physiopathology,surgery Myocardium/pathology Neovascularization, Physiologic Postoperative Period Rats Rats, Nude Rats, Sprague-Dawley Severity of Illness Index Time Factors Transplantation, Heterologous Ventricular Function, Left Ventricular Remodeling
Chemicals
Antigens, CD34
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Kawamoto Atsuhiko
Division of Cardiovascular Research, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA.
Iwasaki Hiroto
Kusano Kengo
Murayama Toshinori
Oyamada Akira
Silver Marcy
Hulbert Christine
Gavin Mary
Hanley Allison
Ma Hong
Kearney Marianne
Zak Victor
Asahara Takayuki
Losordo Douglas W
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
1524-4539
Published
2006-11-14
Epub
2006-00-30
Pages
2163-9
Language
English
Region
United States
NLM ID
0147763
Subset
IM
Grants
NHLBI NIH HHS · HL-53354 · United States
NHLBI NIH HHS · HL-57516 · United States
NHLBI NIH HHS · HL-63414 · United States
NHLBI NIH HHS · HL-77428 · United States
NHLBI NIH HHS · HL-80137 · United States
PHS HHS · HLP01-66957 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]